Who Is Reese Witherspoon's Boyfriend? All About Financier Oliver Haarmann
A source told PEOPLE in October 2024 that the two were "having fun" together
The Legally Blonde actress was seen packing on the PDA with the German financier in July 2025Reese Witherspoon looks smitten with boyfriend Oliver Haarmann!
The Morning Show actress has been dating the German financier since 2024, and the two were seen packing on the PDA during a romantic vacation in July 2025. In photos obtained by PEOPLE, the couple were photographed kissing and hugging while taking in the sights on a yacht off the coast of Saint-Tropez, France.
PEOPLE confirmed in September 2024 that Witherspoon and Haarmann were dating after they were seen spending time together in New York City earlier that year in July. At the time, a source told PEOPLE that Witherspoon was "taking things slow when it comes to dating." Another insider shared that they were "having fun" and that she "often flies between Nashville and N.Y.C. to see him."
Witherspoon's relationship with Haarmann marked her first public romance since getting divorced from Jim Toth in August 2023. The former couple share son Tennessee James Toth. Witherspoon also has daughter Ava Phillippe and son Deacon Phillippe with ex-husband Ryan Phillippe.
So, who is Reese Witherspoon's boyfriend, Oliver Haarmann? Here's everything to know about the financier and their romance.
Haarmann is a graduate of Brown University and Harvard University, the latter of which he earned a master's in business administration from, per his LinkedIn. The financier started his career at KKR, a global investment firm in London, before leaving to found Searchlight Capital Partners, a private equity firm, in 2010.
He has continued his role as a partner where he works with his two cofounders to oversee the firm's activities and portfolio, per his bio on their website.
In December 2023, Sportico reported that Haarmann was in negotiations to buy 10% of the New York Islanders. A couple of months later, The New York Post reported that the Islanders confirmed Haarmann did buy a stake in the team, making him the second person to do so in one year.
Like Witherspoon, Haarmann was previously married. He and his ex-wife, Mala Gaonkar, divorced after welcoming two children together.
Gaonkar is a successful financier herself, starting her own hedge fund, SurgoCap Partners, in 2022. Like her ex-husband, she graduated from Harvard University with a master's in business administration. Before founding her own fund, Gaonkar worked as a founding partner of investment firm Lone Pine Capital.
She also is a writer, collaborating with musician David Byrne to write an immersive theater performance in 2016. The two attended the Academy Awards together in March 2023.
Along with his ex-wife Gaonkar and their friend, Bill & Melinda Gates Foundation veteran Sema Sgaier, Haarmann founded a charity, Surgo Foundation.
'If you don't actually listen to people and find out what they really care about, you're not helping anyone,' Gaonkar told W in May 2017 of the charity's purpose.
Witherspoon and Haarmann dined at L'Artusi in N.Y.C. in July 2024 after flying into the city via helicopter the previous day.
"She enjoys it but doesn't want it to be a big focus. She's busy with work and her son," a source told PEOPLE of Witherspoon's perspective on dating. "These are her biggest priorities."
Before her meetup with Haarmann in the city, Witherspoon spent time with pals Gwyneth Paltrow and Cameron Diaz over the weekend.
Witherspoon's dinner with Haarmann came a year after her divorce with Toth was finalized.
"It is with a great deal of care and consideration that we have made the difficult decision to divorce," Witherspoon and Toth said in a statement when announcing their split in March 2023. "We have enjoyed so many wonderful years together and are moving forward with deep love, kindness and mutual respect for everything we have created together."
She has previously spoken about the difficulties she experienced following her split, telling Harper's Bazaar in August 2023 that sharing her story herself felt more 'authentic' than letting others tell it, as they did during her split with Phillippe.
"To be able to talk to people directly about what's going on in my life and just share it in the way that I share great professional experiences or personal experiences, it feels much more authentic to be able to say things in my own voice and not let somebody else control what's happening," she said.
"Then, of course, there's speculation, but I can't control that. All I can do is be my most honest, forthright self and be vulnerable,' she added.
Witherspoon shared that while the divorce was a 'vulnerable' time for her, she felt 'very connected' with those going through the same thing as her.
One year after they first sparked romance rumors, Witherspoon and Haarmann were seen kissing and hugging while spending time together off the coast of Saint-Tropez. They were photographed swimming in the water while smiling and sharing sweet moments together.
Prior to their yacht outing, a source told PEOPLE in October 2024 that he had been getting to know her two sons.
"He's spending time with her kids too," the insider shared. "Reese loves that he's a businessman and not into Hollywood."
Read the original article on People
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
37 minutes ago
- Yahoo
Prince Harry and King Charles both invited to major UK event as royal reunion is teased
Prince Harry and King Charles may well be reuniting soon — as both royals received invitations to the 2027 Invictus Games. It was revealed last month that the Duke of Sussex, 40, was gearing up to extend an invitation to his estranged father to the ceremony, which is slated to take place in Birmingham in July that year. Helen Helliwell, the CEO of the 2027 event, has expressed hope that both Harry and the monarch, 76, will be in attendance, though teased it's 'too soon to confirm who's going to be there.' 'We would be delighted if the duke were able to come,' she told People. 'He really brings a magical sparkle dust to his interactions, and there is a really special relationship with him and the community.' Helliwell noted that members of the royal family have been ardent 'supporters of the Armed Forces,' and have been advocates of the Invictus Games 'since inception in 2014.' 'We'd be delighted if members of the royal family were able to attend and would very much welcome their presence in a couple of years' time,' she added. The 'Spare' author is believed to have approved the royal guest list and the wording of the invitations already. However, the royals will have a tricky decision to make. The Games will open on July 12, 2027 and conclude on July 17 — which coincides with Queen Camilla's 80th birthday. Celebration planning for Her Majesty's big day is already underway, so it's unclear whether the royals will opt to decline Harry's invitation. It's said that Harry's invitations represent the first time he has publicly reached out to his family since the royal rift began more than five years ago. The 2027 event will mark the first time since the Games have returned to the UK since the very beginning. Helliwell confirmed that the event, which will host 550 athletes from 20 nations, has already secured more than $5.5 million in commercial backing. What's more, she revealed that new sports will be introduced, with pickleball and laser run being thrown into the mix. 'We hope that will bring a new audience,' she explained. It remains to be seen whether Harry's wife, Meghan Markle, and their children Archie and Lilibet will attend. Harry previously insisted this was not an option without 'full police protection' — for which he lost his appeal earlier this year. If the 'Suits' alum, 43, opts not to return to her husband's homeland, it will mark the first Invictus Games she has missed since meeting him in 2016.
Yahoo
2 hours ago
- Yahoo
US tariffs and weak dollar threaten Italian exports, says industry chief
By Giulia Segreti ROME (Reuters) -The only acceptable tariff on European Union exports to the United States would be zero as the bloc is already facing a detrimental exchange rate, the head of Italy's business lobby said on Wednesday. "The real issue is that, to date, not only do we have to consider the burden of tariffs, but we must add to that the euro's appreciation against the dollar," said Confindustria President Emanuele Orsini. The euro has risen by more than 12% against the dollar since the start of the year. Orsini said the dollar's devaluation against the euro "is the biggest in the world" and that Confindustria's projections indicate that it would increase in the coming months, to reach up to 20%. "Any tariff level on top of that is out of control," since the cheaper dollar represents the "highest tariff that (Europe) already faces... making us lame from the start", Orsini said at a conference in Rome. U.S. President Donald Trump on Saturday threatened to impose a 30% tariff on imports from Mexico and the European Union starting on August 1, a level European officials say is unacceptable and would end normal trade between two of the world's largest markets. According to Confindustria, each percentage point of tariffs imposed by the U.S. would translate into a loss of Italian exports worth 874 million euros ($1 billion). The association did not specify over what amount of time. With 30% tariffs, Italy would lose 37.5 billion euros in exports, Orsini said, factoring in the exchange rate impact. Earlier this month he had already warned that tariffs of 10% would have been unsustainable for the Italian economy. Orsini added that Trump's final goal was to "relocate Europe's major companies to the United States" and called on the European Union to set out a plan to hold on to its businesses. ($1 = 0.8608 euros)
Yahoo
2 hours ago
- Yahoo
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2025
Company Announcement Net sales of DARZALEX® in the second quarter of 2025 totaled USD 3,539 million Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN, Denmark; July 16, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX ® in the U.S.), as reported by J&J were USD 3,539 million in the second quarter of 2025. Net trade sales were USD 2,017 million in the U.S. and USD 1,521 million in the rest of the world. Genmab receives royalties on the worldwide net sales of DARZALEX, both the intravenous and SC products, under the exclusive worldwide license to J&J to develop, manufacture and commercialize daratumumab. About Genmab Genmab is an international biotechnology company with a core purpose of guiding its unstoppable team to strive toward improving the lives of patients with innovative and differentiated antibody therapeutics. For more than 25 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational, quantitative and data sciences, resulting in a proprietary pipeline including bispecific T-cell engagers, antibody-drug conjugates, next-generation immune checkpoint modulators and effector function-enhanced antibodies. By 2030, Genmab's vision is to transform the lives of people with cancer and other serious diseases with knock-your-socks-off (KYSO) antibody medicines®. Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit and follow us on LinkedIn and Marisol Peron, Senior Vice President, Global Communications & Corporate AffairsT: +1 609 524 0065; E: mmp@ Andrew Carlsen, Vice President, Head of Investor RelationsT: +45 3377 9558; E: acn@ This Company Announcement contains forward looking statements. The words 'believe,' 'expect,' 'anticipate,' 'intend' and 'plan' and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with preclinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab's most recent financial reports, which are available on and the risk factors included in Genmab's most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law. Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; HexaBody®; DuoHexaBody®, HexElect® and KYSO®. DARZALEX® and DARZALEX FASPRO® are trademarks of Johnson & Johnson. Company Announcement no. 38CVR no. 2102 3884LEI Code 529900MTJPDPE4MHJ122 Genmab A/SCarl Jacobsens Vej 302500 Valby Denmark Attachment 160725_CA38_DARZALEX Q2 2025 salesError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
